The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 1, Pages 96
Publisher
MDPI AG
Online
2020-12-31
DOI
10.3390/cancers13010096
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Mechanisms Controlling Foxp3 Expression in Health and Autoimmunity: From Epigenetic to Post-translational Regulation
- (2020) Alessandra Colamatteo et al. Frontiers in Immunology
- Pancreatic cancer stroma: an update on therapeutic targeting strategies
- (2020) Abdel N. Hosein et al. Nature Reviews Gastroenterology & Hepatology
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
- (2019) Gerald S. Falchook et al. CLINICAL CANCER RESEARCH
- Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
- (2019) Xi Chen et al. Acta Pharmaceutica Sinica B
- Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
- (2019) Gwen Lomberk et al. Nature Communications
- The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
- (2018) Demi S. Houg et al. Molecular Cancer
- Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
- (2018) Gwen Lomberk et al. Nature Communications
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Epigenetics and immunotherapy: The current state of play
- (2017) Jennifer Dunn et al. MOLECULAR IMMUNOLOGY
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- Prognostic role of lymphocyte to monocyte ratio for patients with pancreatic cancer: a systematic review and meta-analysis
- (2017) Wendi Li et al. OncoTargets and Therapy
- Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer
- (2017) Jung-Eun Jang et al. Cell Reports
- BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
- (2016) Yuki Kagoya et al. JOURNAL OF CLINICAL INVESTIGATION
- Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis
- (2016) Sebastian R. Nielsen et al. NATURE CELL BIOLOGY
- Epigenetic drug discovery: breaking through the immune barrier
- (2016) David F. Tough et al. NATURE REVIEWS DRUG DISCOVERY
- BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance
- (2016) N. Tasdemir et al. Cancer Discovery
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- Inflammation in acute and chronic pancreatitis
- (2015) Aida Habtezion CURRENT OPINION IN GASTROENTEROLOGY
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
- (2015) Ignacio Garrido-Laguna et al. Nature Reviews Clinical Oncology
- The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
- (2015) P L Garcia et al. ONCOGENE
- Restoration of E-cadherin Cell-Cell Junctions Requires Both Expression of E-cadherin and Suppression of ERK MAP Kinase Activation in Ras-Transformed Breast Epithelial Cells
- (2015) Quanwen Li et al. NEOPLASIA
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Kras as a key oncogene and therapeutic target in pancreatic cancer
- (2014) Meredith A. Collins et al. Frontiers in Physiology
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
- (2013) T. Shimamura et al. CLINICAL CANCER RESEARCH
- Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
- (2013) D. E. Sanford et al. CLINICAL CANCER RESEARCH
- Inflammatory networks and immune surveillance of pancreatic carcinoma
- (2013) Robert H Vonderheide et al. CURRENT OPINION IN IMMUNOLOGY
- Roles for KRAS in Pancreatic Tumor Development and Progression
- (2013) Marina Pasca di Magliano et al. GASTROENTEROLOGY
- The Epidemiology of Pancreatitis and Pancreatic Cancer
- (2013) Dhiraj Yadav et al. GASTROENTEROLOGY
- MAPK Signaling Is Required for Dedifferentiation of Acinar Cells and Development of Pancreatic Intraepithelial Neoplasia in Mice
- (2013) Meredith A. Collins et al. GASTROENTEROLOGY
- BET bromodomain inhibition suppresses TH17-mediated pathology
- (2013) Deanna A. Mele et al. JOURNAL OF EXPERIMENTAL MEDICINE
- BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
- (2013) A. C. Belkina et al. JOURNAL OF IMMUNOLOGY
- Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
- (2013) Olivier Mirguet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Portal Vein Resection in Borderline Resectable Pancreatic Cancer: A United Kingdom Multicenter Study
- (2013) Reena Ravikumar et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
- (2013) Albrecht Neesse et al. OncoTargets and Therapy
- Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis
- (2012) Angela L. McCleary-Wheeler et al. CANCER LETTERS
- Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development
- (2012) R. Hill et al. MOLECULAR CANCER THERAPEUTICS
- Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
- (2012) Meredith A. Collins et al. PLoS One
- Pancreatitis-Induced Inflammation Contributes to Pancreatic Cancer by Inhibiting Oncogene-Induced Senescence
- (2011) Carmen Guerra et al. CANCER CELL
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
- (2011) Chun-wa Chung et al. JOURNAL OF MEDICINAL CHEMISTRY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer
- (2010) K. T. Liby et al. Cancer Prevention Research
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
- (2009) Anup Dey et al. MOLECULAR BIOLOGY OF THE CELL
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
- Regulatory T Cells: Mechanisms of Differentiation and Function
- (2007) Steven Z. Josefowicz et al. Annual Review of Immunology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started